Mounjaro, Zepbound shortage eases
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors,
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. As products move through the supply chain,
Eli Lilly’s Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
pharmaphorum5h
Mounjaro and Zepbound shortages over, declares FDA
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
Mounjaro is here and it’s the ‘King Kong’ of weight loss jabs, but there’s a catch...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...
NHS proposes phased launch for Eli Lilly’s Mounjaro
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
National Health Executive5h
Mounjaro: NICE consults on NHSE proposals for ’unprecedented’ obesity drug roll-out
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.
FiercePharma21h
NHS England proposes phased rollout for Eli Lilly's star obesity drug
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
Facebook has become the place to sell leftover Ozempic, other weight loss drugs — as NYC sellers take advantage of shortages and high prices
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.